Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

  • Yosef Yarden
  • Moshe Elkabets

Part of the Resistance to Targeted Anti-Cancer Therapeutics book series (RTACT, volume 15)

Table of contents

  1. Front Matter
    Pages i-xx
  2. Livio Trusolino, Simonetta M. Leto
    Pages 1-27
  3. Jennifer L. Hsu, Mien-Chie Hung
    Pages 51-66
  4. Pau Castel, Maurizio Scaltriti
    Pages 117-146
  5. Konstantinos V. Floros, Anthony C. Faber, Hisashi Harada
    Pages 147-180
  6. Wolf Ruprecht Wiedemeyer
    Pages 181-210
  7. Nili Dahan, Ksenia Magidey, Yuval Shaked
    Pages 211-236
  8. Back Matter
    Pages 237-242

About this book

Introduction

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.

Keywords

Anti-cancer Kinases Resistance Tyrosine therapeutics

Editors and affiliations

  • Yosef Yarden
    • 1
  • Moshe Elkabets
    • 2
  1. 1.Department of Biological RegulationWeizmann Institute of ScienceRehovotIsrael
  2. 2.Department of Microbiology, Immunology and GeneticsBen-Gurion University of the NegevBeer-SheevaIsrael

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-319-67932-7
  • Copyright Information Springer International Publishing AG, part of Springer Nature 2018
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-3-319-67930-3
  • Online ISBN 978-3-319-67932-7
  • Series Print ISSN 2196-5501
  • Series Online ISSN 2196-551X
  • About this book
Industry Sectors
Biotechnology
Consumer Packaged Goods
Pharma